Genmab — Juli 2018
-
Tak Bulder. Det er også mit indtryk, at ema ikke fraviger deres procedurer for noget som helst. Når nu klokken blev stoppet på processen, så kan man ikke slippe billigere end med en måneds forsinkelse.
-
God morgen.
-
God morgen
-
Genmab gains exclusive access to multiple novel proprietary tumor targets identified by Immatics Biotechnologies’ XPRESIDENT
technology
Creation of novel immuno-oncology drugs combining Genmab and Immatics’ proprietary technologies
Genmab responsible for development, manufacturing and commercialization worldwide
Immatics to receive upfront payment of USD 54 million from Genmab -
The deal strengthens Genmab’s position in immuno-oncology by combining Genmab's proprietary technologies and antibody know-how with Immatics' XPRESIDENT
targets and T-cell receptor (TCR) capabilities. Genmab will receive an exclusive license to three proprietary targets from Immatics, with an option to license up to two additional targets at predetermined economics. The companies will conduct joint research, funded by Genmab, on multiple antibody and/or TCR-based bispecific therapeutic product -
Genmab may elect to progress any resulting product candidates, and will be responsible for development, manufacturing and worldwide commercialization. For any products that are commercialized by Genmab, Immatics will have an option to limited co-promotion efforts in selected countries in the EU.
-
This collaboration with Immatics gives us the opportunity to combine our unique technologies and expertise to create differentiated novel next-generation therapies. We very much look forward to this exciting partnership in the field of cancer immunotherapy,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab
-
Genmab har indgået et strategisk partnerskab med det tyske selskab Immatics omhandlende udvikling af immunterapi.
Det oplyser det danske biotekselskab torsdag morgen i en meddelelse.
Som en del af partnerskabet vil Genmab betale Immatics et kontantbeløb på 54 mio. dollar, og Immatics er berettiget til at modtage op til 550 mio. dollar i udvikling samt regulatoriske og kommercielle milepælsbetalinger for hvert produkt såvel som forskellige royalties for salget.
-
Har også læst den.
-
Mon det er kurspåvirkende?
-
Det burde ikke betyde noget kursmæssigt. Denne type programmer har den indbyggede fordel, at risikoen på lange strækninger bliver sendt ud af huset.
-
Dejligt at der sker noget. Når nu GEN vil kontrollere vores penge, så skal de dælme også arbejde (pengene)
-
...men er det her ikke t-celle terapi....
-
Om immatics xpresident program her https://immatics.com/x-president.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind